Novartis (NOVN) Stock Overview
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 5/6 |
NOVN Community Fair Values
Create NarrativeSee what 155 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Novartis AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 116.80 |
| 52 Week High | CHF 131.00 |
| 52 Week Low | CHF 90.40 |
| Beta | 0.49 |
| 1 Month Change | -1.30% |
| 3 Month Change | -6.66% |
| 1 Year Change | 27.69% |
| 3 Year Change | 29.05% |
| 5 Year Change | 47.29% |
| Change since IPO | 213.98% |
Recent News & Updates
Recent updates
NOVN: Pipeline Progress And Steady Dividend Will Support Balanced Future Outlook
Analysts now see slightly lower upside for Novartis, trimming their price target by around CHF 0.52. This reflects only marginal shifts in fair value, revenue growth, profit margin and future P/E assumptions.NOVN: Dermatology And Immunology Pipeline Plus Dividend Will Shape Balanced Outlook
Analysts have slightly reduced their Novartis price target to CHF121.41 from CHF121.50. This change reflects updated assumptions that combine a somewhat lower revenue growth outlook with a modestly higher profit margin and a small adjustment to the future P/E multiple.NOVN: Dermatology Pipeline, RLT Expansion And Dividend Will Shape Balanced Returns
Analysts have modestly raised their Novartis price target from CHF 117.49 to CHF 121.50, citing updated assumptions for revenue growth, profit margins and future P/E as key drivers of the revision. What's in the News Cosentyx received US FDA approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa, making it the only IL-17A inhibitor available for this group and expanding Novartis' dermatology footprint in a chronic inflammatory skin disease that often begins around puberty.NOVN: Dividend Progress And US Manufacturing Expansion Will Shape Balanced Future Returns
Analysts have nudged their fair value estimate for Novartis up from about CHF116.24 to around CHF117.49. This mainly reflects slightly higher expected profit margins and a modestly higher future P/E assumption, while revenue growth expectations are a touch lower.NOVN: Autoimmune Pipeline Readouts And Dividend Growth Will Shape Balanced Future Returns
Analysts have raised their Novartis price target from CHF 113.58 to CHF 116.24. This reflects updated assumptions that combine slightly higher revenue growth with a modestly lower profit margin and a higher future P/E multiple.
Radioligand And Gene Therapy Platforms Will Support A Stronger Long Term Outlook
Catalysts About Novartis Novartis is a global pharmaceutical company focused on patented medicines across oncology, cardiovascular, immunology, neuroscience and gene therapy. What are the underlying business or industry changes driving this perspective?NOVN: US Infrastructure Buildout And Autoimmune Pipeline Will Shape Balanced Future Returns
Analysts have nudged their fair value estimate for Novartis up from $110.20 to $113.58, citing updated assumptions around modestly higher revenue growth, slightly stronger profit margins, and a marginally lower future P/E multiple. What's in the News Canada's Drug Agency issued a positive draft recommendation to reimburse Kisqali ribociclib tablets for eligible high risk early breast cancer patients, following Health Canada approval in June 2025 and Phase III data indicating reduced risk of recurrence across a broad HR+/HER2- stage II-III population (Key Developments).Novartis (VTX:NOVN) Has Announced That It Will Be Increasing Its Dividend To $3.70
Novartis AG ( VTX:NOVN ) will increase its dividend from last year's comparable payment on the 12th of March to $3.70...Novartis AG (VTX:NOVN) Full-Year Results: Here's What Analysts Are Forecasting For This Year
It's been a good week for Novartis AG ( VTX:NOVN ) shareholders, because the company has just released its latest...NOVN: US Buildout And Late-Stage Autoimmune Pipeline Will Shape Future Returns
Analysts now set their Novartis price target at about $110.20, up slightly from roughly $110.00. This reflects small tweaks to assumptions around long term revenue growth, profit margins and future P/E expectations.NOVN: Future Returns Will Reflect US Buildout And Late-Stage Pipeline Delivery
Analysts have raised their price target for Novartis to $109.99 from $106.64, citing updated assumptions for slightly stronger revenue growth, higher profit margins, and a modestly lower future P/E multiple. What's in the News Novartis plans a new 35,000 square foot radioligand therapy manufacturing facility in Winter Park, Florida, as part of its previously announced US$23b US investment.NOVN: Future Returns Will Reflect US Investment And Pipeline Execution Under Stable Outlook
Analysts have modestly reduced their price target on Novartis to approximately $107 per share from about $109. This reflects slightly lower margin expectations that more than offset improved revenue growth assumptions under an unchanged risk profile.NOVN: Future Returns Will Reflect Pipeline Progress And Expanding US Manufacturing
Analysts have modestly raised their price target on Novartis to approximately $109 from about $105. This change reflects a higher expected future valuation multiple, which more than offsets slightly lower long term revenue growth and profit margin assumptions.NOVN: Future Outlook Will Balance New Approvals And Expanding US Operations
Narrative Update on Novartis Novartis’ analyst price target has been revised upward from $102.12 to $104.58. This change reflects modest adjustments in fair value and expectations based on analysts’ latest evaluations of the company’s growth and profitability outlook.We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative
Even though Novartis AG's ( VTX:NOVN ) recent earnings release was robust, the market didn't seem to notice. Investors...NOVN: Future Trial Data And Pipeline Advancements Will Support Steady Returns
Analysts have raised their fair value estimate for Novartis from $98.60 to $102.12. They cite improved revenue growth outlook and stronger profit margins as key drivers of the upward revision.China Expansion And Advanced Therapies Will Drive Future Upside
Analysts have slightly reduced their price target for Novartis to $98.60 from $99.08, as they cite marginally lower expectations for future revenue growth and profit margins. What's in the News CHMP of the European Medicines Agency recommended marketing authorization for Scemblix (asciminib) for all lines of treatment in adults with chronic myeloid leukemia, based on positive Phase III data.China Expansion And Advanced Therapies Will Drive Future Upside
Analysts have raised their fair value estimate for Novartis from $97.49 to $99.08. They cite improved revenue growth projections, even though profit margin expectations have decreased slightly.China Expansion And Advanced Therapies Will Drive Future Upside
Novartis's future P/E multiple has materially contracted even as consensus revenue growth forecasts edged up, resulting in a marginal decrease in fair value from CHF99.36 to CHF97.49. What's in the News Novartis and Argo Biopharmaceutical entered a strategic collaboration on multiple cardiovascular assets, granting Novartis ex-China licensing and P&L options on several siRNA pipeline compounds; Argo received $160M upfront, with milestones and royalties potentially totaling up to $5.2B.These 4 Measures Indicate That Novartis (VTX:NOVN) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Novartis AG (VTX:NOVN) Doing What It Can To Lift Shares
With a price-to-earnings (or "P/E") ratio of 17.8x Novartis AG ( VTX:NOVN ) may be sending bullish signals at the...Shareholder Returns
| NOVN | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 3.0% | 1.8% | 0.4% |
| 1Y | 27.7% | 29.3% | 6.1% |
Return vs Industry: NOVN underperformed the Swiss Pharmaceuticals industry which returned 29.3% over the past year.
Return vs Market: NOVN exceeded the Swiss Market which returned 6.1% over the past year.
Price Volatility
| NOVN volatility | |
|---|---|
| NOVN Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in CH Market | 8.2% |
| 10% least volatile stocks in CH Market | 2.5% |
Stable Share Price: NOVN has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: NOVN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 75,267 | Vas Narasimhan | www.novartis.com |
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.
Novartis AG Fundamentals Summary
| NOVN fundamental statistics | |
|---|---|
| Market cap | CHF 222.87b |
| Earnings (TTM) | CHF 10.61b |
| Revenue (TTM) | CHF 44.34b |
Is NOVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVN income statement (TTM) | |
|---|---|
| Revenue | US$56.58b |
| Cost of Revenue | US$13.83b |
| Gross Profit | US$42.75b |
| Other Expenses | US$29.21b |
| Earnings | US$13.53b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 21, 2026
| Earnings per share (EPS) | 7.09 |
| Gross Margin | 75.55% |
| Net Profit Margin | 23.92% |
| Debt/Equity Ratio | 115.8% |
How did NOVN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/15 01:25 |
| End of Day Share Price | 2026/05/13 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novartis AG is covered by 58 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |
| Gerhard Schwarz | Baader Helvea Equity Research |